Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
bioAffinity Technologies, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
10/10/2023 SC 13G Joyce Roby reports a 6.4% stake in bioAffinity Technologies, Inc.
09/26/2023 3 Joyce Roby (Director) has filed a Form 3 on bioAffinity Technologies, Inc.
08/14/2023 8-K Quarterly results
Docs: "bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update SAN ANTONIO – bioAffinity Technologies, Inc. , a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and six months ended June 30, 2023, and provided a business update. Highlights from the second quarter of 2023 and subsequent weeks included: Corporate and Commercial Highlights ● The American Medical Association issued a Current Procedural Terminology code for use with CyPath Lung with an effective date of Oct. 1, 2023. CPT codes provide a uniform system to identify medical services and procedures and seek reimbursement from private payers and public health insuranc..."
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 4 GIRGENTI STEVEN (Executive Chairman) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Granted 8,227 shares @ $2.28, valued at $18.8k
Granted 9,920 shares @ $1.89, valued at $18.7k
Granted 10,245 shares @ $1.83, valued at $18.7k
Granted 26,315 shares @ $2.28, valued at $60k
07/28/2023 8-K Quarterly results
07/06/2023 4 GIRGENTI STEVEN (Executive Chairman) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Granted 8,227 shares @ $2.28, valued at $18.8k
Granted 9,920 shares @ $1.89, valued at $18.7k
Granted 10,245 shares @ $1.83, valued at $18.7k
07/06/2023 4 Rubin Gary D (10% Owner) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Granted 8,227 shares @ $2.28, valued at $18.8k
Granted 9,920 shares @ $1.89, valued at $18.7k
Granted 10,245 shares @ $1.83, valued at $18.7k
07/06/2023 4 Zannes Maria (President, CEO) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Granted 8,227 shares @ $2.28, valued at $18.8k
Granted 9,920 shares @ $1.89, valued at $18.7k
Granted 26,178 shares @ $1.91, valued at $50k
Granted 10,245 shares @ $1.83, valued at $18.7k
07/06/2023 4 KNIGHT PETER S (Director) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Granted 8,227 shares @ $2.28, valued at $18.8k
Granted 9,920 shares @ $1.89, valued at $18.7k
Granted 10,245 shares @ $1.83, valued at $18.7k
07/06/2023 4 Dougherty Michael Philip (CFO) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Granted 52,356 shares @ $1.91, valued at $100k
06/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF",
"bioAffinity Technologies, Inc. Amended and Restated 2014 Equity Incentive Plan 1. Purposes. Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are the Employees, Directors and Consultants of the Company and its Affiliates. Available Stock Awards. The purpose of the Plan is to provide a means by which eligible recipients of Stock Awards may be given an opportunity to benefit from increases in value of the Common Stock through the granting of the following Stock Awards: Incentive Stock Options, Nonstatutory Stock Options, and restricted stock awards. General Purpose. The Company, by means of the Plan, seeks to retain the services of the group of persons eligible to receive Stock Awards, to secure and retain the services of new members of this group and to provide i..."
05/15/2023 8-K Quarterly results
Docs: "bioAffinity Technologies Reports First Quarter 2023 Financial Results"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 3 Dougherty Michael Philip (CFO) has filed a Form 3 on bioAffinity Technologies, Inc.
04/25/2023 8-K Quarterly results
04/19/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/19/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
04/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies to Ring Nasdaq Closing Bell Today"
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
03/24/2023 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023"
03/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023"
03/07/2023 4 Perlmutter Nathan M (10% Owner) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Converted 31,780 shares @ $4.2, valued at $133.5k
Converted 87,851 shares @ $4.2, valued at $369k
Converted 27,378 shares @ $4.2, valued at $115k
Converted 14,811 shares @ $6.75, valued at $100k
Converted options to buy @ $0
Converted 103,682 options to buy @ $0
Granted 24,602 options to buy @ $0
Granted 71,428 options to buy @ $0
Granted 23,809 options to buy @ $0
Granted 47,935 options to buy @ $5.25, valued at $251.7k
03/07/2023 3 Perlmutter Nathan M (10% Owner) has filed a Form 3 on bioAffinity Technologies, Inc.
03/07/2023 4 Meghji Mohsin Y (Director) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Converted 40,907 shares @ $3.67, valued at $150.1k
Converted 286,349 options to buy @ $0
03/07/2023 3 Meghji Mohsin Y (Director) has filed a Form 3 on bioAffinity Technologies, Inc.
02/13/2023 8-K Quarterly results
01/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research"
01/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Tiberend Strategic Advisors, Inc."
12/15/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench"
12/05/2022 4 Zannes Timothy P (Secretary, EVP, Gen. Counsel) has filed a Form 4 on bioAffinity Technologies, Inc.
Txns: Granted 3,619 shares @ $0
12/05/2022 3 Zannes Timothy P (Secretary, EVP, Gen. Counsel) has filed a Form 3 on bioAffinity Technologies, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy